Halozyme Therapeutics Adds Director

Halozyme Therapeutics Names Kenneth Kelley to Board of Directors San Diego-based Halozyme Therapeutics announced that Kenneth Kelley has been named to its Board of Directors. Kelley was previously a General Partner at Latterell Venture Partners, founder of IntraBiotics Pharmaceuticals, and an Associate at Insitutional Venture Partners. Halozyme is developing recombinant human enzyme technology to replace animal-slaughterhouse derived enzymes.